New report shows that HPV vaccine trials can be significantly shortened

A new report from a Working Group convened by the International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, and the United States National Cancer Institute (NCI) shows how the evaluation and licensing of prophylactic human papillomavirus (HPV) vaccines could be significantly accelerated.Communiqué de Presse No 226Rapport du Groupe de travail du CIRC 7